✦ LIBER ✦

EPA-0790 – All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials

✍ Scribed by Baker, R.; Fleischhacker, W.W.; Sanchez, R.; Tsai, L.F.; Peters-Strickland, T.; Eramo, A.; Kostic, D.; Kane, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Poster #S233 ALL-CAUSE DISCONTINUATION A

✍ Eramo, Anna; Fleischhacker, W. Wolfgang; Sanchez, Raymond; Tsai, Lan-Feng; Peter 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 89 KB

A Pooled Analysis of Two Randomized, Dou

✍ Michael E. Geisser; Robert H. Palmer; R. Michael Gendreau; Yong Wang; Daniel J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

The efficacy, safety, and tolerability o

✍ Ira D. Glick; Raymond Mankoski; James M. Eudicone; Ronald N. Marcus; Quynh-Van T 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Tu1403 Safety and Tolerability Profile o

✍ Chang, Lin; Chey, William D.; Drossman, Douglas A.; Lembo, Anthony; Pimentel, Ma 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Functional Outcomes with Aripiprazole On

✍ Fleischhacker, W.W.; Perry, P.; Sanchez, R.; Jin, N.; Peters-Strickland, T.; Joh 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Safety and tolerability of rifaximin for

✍ Schoenfeld, P.; Pimentel, M.; Chang, L.; Lembo, A.; Chey, W. D.; Yu, J.; Paterso 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB